Citius Pharmaceuticals (CTXR) is hands down one of the most exciting long-term opportunities we have come across since we first launched the Biotech Stock Review in 2002.
In companies this small, with such a large insider ownership stake (60%), significant news in 2020 or 2021 could spur the shares far beyond what current fundamentals might normally warrant.
The Company’s Mino-Lok technology while complex is easy for investors to understand. Their market is huge, estimated at $500 million to $1 billion annually, and fairly-easy for investors to identify. The need for Mino-Lok is rather obvious as we will later explain. Also, studies to date have proven it to be much safer, more effective and less expensive than the alternatives and once again, easy for investors to grasp.
In sum, Citius has pretty much everything we look for in a Biotech idea including (if not most importantly) a tiny market valuation with only 31 million shares outstanding, plus top-rated management with decades of proven success. Enough success to enable them to invest more than $27 million of their own money into Citius. This is an opportunity not to be ignored.
Client, see report for disclosure and disclaimer related details.
